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Aims The efficacy of durable polymer drug-eluting stents (DES) is delivered at the expense of delayed healing of the
stented vessel. Biodegradable polymer DES aim to avoid this shortcoming and may potentially improve long-term
clinical outcomes, with benefit expected to accrue over time. We sought to compare long-term outcomes in patients
treated with biodegradable polymer DES vs. durable polymer sirolimus-eluting stents (SES).
Methods
and results
We pooled individual patient data from three large-scale multicentre randomized clinical trials (ISAR-TEST 3, ISAR-
TEST 4, and LEADERS) comparing biodegradable polymer DES with durable polymer SES and assessed clinical out-
comes during follow-up through 4 years. The efficacy endpoint of interest was target lesion revascularization and the
safety endpoint of interest was definite stent thrombosis. Out of 4062 patients included in the present analysis, 2358
were randomly assigned to treatment with biodegradable polymer DES (sirolimus-eluting, n ¼ 1501; biolimus-eluting,
n ¼ 857) and 1704 patients to durable polymer SES. No heterogeneity across the trials was observed in analyses of
the primary and secondary endpoints. At 4 years, the risk of target lesion revascularization was significantly lower
among patients treated with biodegradable polymer DES vs. durable polymer SES (hazard ratio 0.82, 95% CI
0.68–0.98, P ¼ 0.029). In addition, the risk of stent thrombosis was significantly reduced with biodegradable
polymer DES vs. durable polymer SES (hazard ratio 0.56, 95% CI 0.35–0.90, P ¼ 0.015), driven by a lower risk of
very late stent thrombosis (hazard ratio 0.22, 95% CI 0.08–0.61, P ¼ 0.004). In keeping with this, in landmark analysis
between 1 and 4 years, the incidence of myocardial infarction was lower for patients treated with biodegradable
polymer DES vs. durable polymer SES (hazard ratio 0.59, 95% CI 0.73–0.95, P ¼ 0.031).
Conclusion Biodegradable polymer DES improve safety and efficacy compared with durable polymer SES during long-term
follow-up to 4 years.
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Introduction
Drug-eluting stents (DES) with controlled release of anti-
proliferative drugs from durable polymer coatings provide potent
suppression of neointimal hyperplasia and markedly reduced the
risk of repeat revascularization compared with bare metal
stents.1 –3 However, the use of early generation durable polymer
DES was associated with an increased risk of very late (.1 year)
stent thrombosis compared with bare metal stents.4– 6 Animal
experiments, human autopsy studies, and investigation of throm-
bosed DES specimens using intravascular ultrasound demonstrated
that very late ST is related to delayed arterial healing and remodelling
of the stented vessel owing to ongoing inflammation.7– 11 The per-
sistence of durable polymer coatings after completion of the
drug release has been implicated as a potential culprit for this
chronic inflammatory response.8,12,13
Biodegradable polymer-based DES, with controlled drug-release
followed by subsequent degradation of the polymer coating, may
potentially improve long-term clinical outcomes after coronary
stenting, by rendering the stent surface similar to that of a bare
metal stent and free of a chronic inflammatory stimulus. Biodegrad-
able polymer-based DES have been established as a safe and effect-
ive alternative to durable polymer-based stent platforms as
evidenced in several randomized clinical trials.14– 17 Moreover, an
optical coherence tomography study suggested improved healing
of the stented coronary segment following treatment with bio-
degradable polymer DES compared with durable polymer
sirolimus-eluting stents (SES) at 9 months.18 However, the poten-
tial clinical advantage of biodegradable polymer DES over durable
polymer DES may be expected to emerge first after long-term
follow-up, where the incidence of late adverse events related to
impaired vessel healing—such as stent thrombosis—is hypothe-
sized to be lower. Against this background, we pooled results
from the three largest randomized clinical trials comparing bio-
degradable polymer DES with durable polymer SES14– 16 incorpor-
ating clinical follow-up to 4 years.
Methods
Patient population
We performed a patient-level pooled analysis of the three largest mul-
ticentre, randomized clinical trials comparing biodegradable polymer
DES with durable polymer SES for coronary revascularization: the
ISAR-TEST 3 trial (ClinicalTrials.gov identifier: NCT00350454),14 the
ISAR-TEST 4 trial (ClinicalTrials.gov identifier: NCT00598676),15 and
the LEADERS trial (ClinicalTrials.gov identifier: NCT00389220).16 A
total of 4062 patients were included in the present analysis, 2358 of
these were randomly allocated to treatment with biodegradable
polymer DES [n ¼ 1501, sirolimus-eluting (Yukon Choice, stent back-
bone produced by Translumina, Hechingen, Germany); n ¼ 857,
biolimus-eluting (BioMatrix Flex, Biosensors Inc., Newport Beach, CA,
USA)] and 1704 patients to durable polymer SES (Cypher Select,
Cordis, Miami Lakes, FL, USA). Detailed descriptions relating to the
design of the three trials are reported in the primary publications;14 –16
a summary of the principal trial characteristics is reported in Table 1.
Patients were followed up clinically out to 4 years after enrolment by
the investigating sites.
Procedural and discharge medications
In all three trials, an oral dose loading dose of 300–600 mg clopidogrel
was administered before or at the time of the procedure. During the
procedure, all patients received unfractionated heparin or bivalirudin,
whereas the use of glycoprotein IIb/IIIa antagonists was left at the dis-
cretion of the operators. All patients were discharged on acetylsalicylic
acid of at least 75 mg daily indefinitely and clopidogrel 75 mg daily for
at least 6 months in the ISAR-TEST 3 and ISAR-TEST 4 trials, and at
least 12 months in the LEADERS trial.
Endpoints and definitions
The efficacy endpoint of interest of the present analysis was target
lesion revascularization; the safety endpoint of interest was definite
stent thrombosis. Additional endpoints analysed were all-cause mortal-
ity, cardiac death, myocardial infarction, and definite or probable stent
thrombosis. Target lesion revascularization was defined as any clinically
indicated repeat revascularization (percutaneous or surgical) of the
target lesion. The definition of clinically indicated revascularization
was consistent across the included trials. Cardiac death was defined
as death due to immediate cardiac causes or complications related
to the procedure, as well as any death in which a cardiac cause
could not be excluded. Myocardial infarction in the ISAR-TEST 4
trial refers to target-vessel myocardial infarction; in the ISAR-TEST 3
and LEADERS trials, any myocardial infarction was included. Stent
thrombosis was defined according to the Academic Research Consor-
tium criteria.19
Trial quality assessment
All trials were assessed for bias using components recommended by
the Cochrane Collaboration,20 including sequence generation of the al-
location; allocation concealment; blinding of participants, personnel,
and outcome assessors; selective outcome reporting; and other
sources of bias. Trials with high or unclear risk for bias for any one
of the first three components were considered as trials with high
risk of bias. Otherwise, they were considered as trials with low risk
of bias.
Statistical analysis
Continuous data are presented as mean (+SD) or median (25th–75th
percentiles). Categorical data are presented as counts and proportions
(%). Meta-analysis was performed on individual patient data according
to intention to treat. We performed survival analyses using the
Mantel–Cox method stratified by the trial. Trials in which the event
of interest was not observed in either treatment group were
omitted from the analysis of that event. In case only one of the
groups of an individual trial had no event of interest, the estimate of
treatment effect estimate and its standard error were calculated
after adding 0.5 to each cell of the 2 × 2 table for that trial.21 We
used the Cochran test to assess heterogeneity across trials. Also, we
calculated the I2 statistic to measure the consistency between trials
with values of 25, 50, and 75% showing respectively, low, moderate,
and high inconsistency.22 Hazard ratios from individual trials were
pooled using the DerSimonian and Laird method for random
effects.23 Results were considered statistically significant at two-sided
P, 0.05. Statistical analysis was performed using the Stata software,
version 9.2 (Stata Corp, College Station, TX, USA). Survival curves
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Table 1 Summary of included trials
Study No. of
patients
Stent
type
Patients pooled in
the current analysis
according to the
stent type
Primary endpoint Inclusion
criteria
Exclusion criteria Baseline characteristics
Clinical Lesion Mean age,
years (SD)
Male,
%
ACS,
%
Diabetes,
%
Clinical
follow-up
Angiographic
follow-up
ISAR-TEST
3
605 DP SES
BP SES
PF SES
DP SES (n ¼ 202)
BP SES (n ¼ 202)
In-stent late luminal
loss
Symptoms or
evidence of
ischaemia
Acute MI,
cardiogenic
shock
In-stent
restenosis, left
main lesion,
bypass graft
lesion
66.1 (10.7) 79.3 30.9 27.4 4 years 6–8 months
ISAR-TEST
4
2603 BP SES
DP SES
DP EES
BP SES (n ¼ 1299)
DP SES (n ¼ 652)
Composite of cardiac
death, target
vessel MI, clinically
indicated TLR at
12 months
Symptoms or
evidence of
ischaemia
Cardiogenic
shock
In-stent
restenosis, left
main lesion,
bypass graft
lesion
66.7 (10.9) 76.1 40.7 28.9 4 years 6–8 months
LEADERS 1707 BP BES
DP SES
BP BES (n ¼ 857)
DP SES (n ¼ 850)
Composite of cardiac
death, MI, clinically
indicated TVR at 9
months
No restriction None None 64.5 (10.7) 74.8 55.2 24.2 4 years 9 months
ACS, acute coronary syndrome; BES, biolimus-eluting stent; BP, biodegradable polymer; DP, durable polymer; EES, everolimus eluting stent; MI, myocardial infarction; PF, polymer-free; SES, sirolimus-eluting stent; TLR, target lesion
revascularization; TVR, target vessel revascularization.
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are presented as simple, non-stratified Kaplan–Meier curves across all
trials and constructed with the use of S-Plus software version 4.5 (In-
sightful Corporation, Seattle, WA, USA).
Role of funding source
The sources of funding for this study had no role in the design, data
collection, analysis, interpretation of data, writing of the report, or
the decision to submit the paper for publication.
Results
A total of 4062 patients were included in the present analysis, of
which 2358 patients had been randomly assigned to treatment
with biodegradable polymer DES—1501 patients with sirolimus-
eluting and 857 patients with biolimus-eluting stents—and 1704
patients to treatment with durable polymer SES.
No heterogeneity across the trials was observed in the analyses
of the primary and secondary endpoints. All three included trials
were assessed as low risk for bias. Clinical outcomes up to 4
years are summarized in Table 2 with landmark analyses between
1 and 4 years in Table 3.
In terms of the efficacy endpoint, the risk of target lesion revas-
cularization was significantly lower among patients treated with
biodegradable polymer DES vs. durable polymer SES (hazard
ratio 0.82, 95% CI 0.68–0.98, P ¼ 0.029) (Figure 1).
Regarding safety endpoints, the risk of definite stent thrombosis
was significantly reduced with biodegradable polymer DES when
compared with durable polymer SES (hazard ratio 0.56, 95% CI
0.35–0.90, P ¼ 0.015) (Figure 2). This difference was primarily
driven by a significant risk reduction in terms of very late definite
stent thrombosis with biodegradable polymer DES vs. durable
polymer SES (hazard ratio 0.22, 95% CI 0.08–0.61, P ¼ 0.004)
(Figure 2). The risk of definite or probable stent thrombosis was
also lower among patients treated with biodegradable polymer
DES (hazard ratio 0.68, 95% CI 0.46–1.01, P ¼ 0.054). In landmark
analysis between 1 and 4 years, patients treated with biodegradable
polymer DES when compared with durable polymer SES had sig-
nificantly lower risk of myocardial infarction (hazard ratio 0.59,
95% CI 0.37–0.95, P ¼ 0.031).
Discussion
Our findings show that the use of biodegradable polymer DES
improves safety and efficacy compared with durable polymer SES
during long-term follow-up.
Early generation durable polymer DES have been associated
with increased rates of very late (.1 year) stent thrombosis com-
pared with bare metal stents,2,4 –6 a difference that emerged par-
ticularly among patients with ‘off-label’ indications.24– 26 The
pathophysiological mechanisms underlying this adverse event are
delayed arterial healing, a process in which the durable polymer
coatings used for controlling drug release may have an important
aetiological role.8– 12 In addition, an excess of late in-stent resten-
osis with durable polymer DES compared with bare metal stents
can be detected at angiographic surveillance, and while the clinical
impact is likely low, this is interpreted as another expression of
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Table 2 Clinical outcomes through 4 years
Biodegradable polymer DES
(n5 2358)
Durable polymer SES
(n5 1704)
Hazard ratio (95% CI) P-value
1 year
Death 93 (4.0) 64 (3.8) 0.97 (0.70–1.34) 0.85
Cardiac death 55 (2.4) 47 (2.8) 0.80 (0.54–1.19) 0.26
Myocardial infarction 106 (4.5) 67 (4.4) 1.18 (0.86–1.61) 0.31
Definite stent thrombosis 26 (1.1) 26 (1.5) 0.80 (0.47–1.38) 0.43
Clinically indicated TLR 174 (7.6) 145 (8.8) 0.82 (0.65–1.03) 0.09
Cardiac death or myocardial infarction 145 (6.2) 103 (6.1) 1.02 (0.78–1.31) 0.91
Cardiac death, myocardial infarction, or
clinically indicated TLR
287 (12.3) 223 (13.3) 0.89 (0.75–1.06) 0.20
4 years
Death 207 (9.3) 163 (10.0) 0.90 (0.73–1.11) 0.32
Cardiac death 113 (5.2) 95 (5.9) 0.87 (0.66–1.15) 0.34
Myocardial infarction 135 (6.0) 109 (6.8) 0.96 (0.74–1.24) 0.74
Definite stent thrombosis 30 (1.3) 44 (2.8) 0.56 (0.35–0.90) 0.015
Clinically indicated TLR 264 (12.0) 217 (13.7) 0.82 (0.68–0.98) 0.029
Cardiac death or myocardial infarction 221 (9.9) 187 (11.6) 0.89 (0.73–1.09) 0.25
Cardiac death, myocardial infarction, or
clinically indicated TLR
429 (19.0) 350 (21.6) 0.85 (0.74–0.98) 0.027
Events are reported as number (percentage from the Kaplan–Meier estimate); hazard ratios and P-values were calculated using random effects meta-analysis. CI, confidence
interval; DES, drug-eluting stents; SES, sirolimus-eluting stents; TLR, target lesion revascularization.
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impaired vascular healing, with a chronic inflammatory response
provoking a delayed low-grade cellular proliferation.27– 29
Biodegradable polymer DES have been developed with the
aim of reducing the adverse long-term sequelae related to
the persistence of durable polymers in the arterial wall beyond
the period necessary to control drug release. Several clinical
trials have confirmed the safety and efficacy of biodegradable
polymer DES when compared with durable polymer DES,14–17
although the potential clinical benefit of biodegradable polymer
DES is hypothesized to emerge only during the late post-
intervention phase, once the polymer coating is completely
resorbed.
The findings of the current study may be regarded as novel and
important for at least 3 reasons. First, with respect to safety, our
findings show for the first time a statistically significant and likely
clinically important risk reduction for definite stent thrombosis in
favour of biodegradable polymer DES compared with durable
polymer-based SES at 4 years (HR 0.56, 95% CI 0.35–0.90,
P ¼ 0.015). Importantly, this difference was not apparent when
the trials included in this study were analysed separately, a
finding mainly attributable to a lack of statistical power.30,31
Indeed, the powering of individual trials to detect differences in
rarely occurring adverse safety events such as stent thrombosis
has not been adequate in any study to date and was one of the
key reasons we undertook the present analysis. Secondly, in a land-
mark analysis between 1 and 4 years, we could demonstrate that
the incidence of myocardial infarction was significantly lower
with biodegradable polymer vs. durable polymer DES (hazard
ratio 0.59, 95% CI 0.73–0.95, P ¼ 0.031). This risk reduction in
late adverse clinical events associated with the use of biodegrad-
able polymer DES represents a major benefit, by overcoming the
principal limitation of early generation durable polymer DES.
Taken together, both of these new findings may be regarded as
an important step in the proof-of-concept chain of investigation
for biodegradable polymer DES. Thirdly, the enhanced safety
profile does not occur at the expense of antirestenotic efficacy.
In actual fact, target lesion revascularization was significantly
lower at 4 years in patients treated with biodegradable polymer
DES (hazard ratio 0.82, 95% CI 0.68–0.98, P ¼ 0.029), a finding
not observed in the individual trials and potentially related to the
absence of a late catch up phenomenon with biodegradable
polymer stents. It may therefore be hypothesized that biodegrad-
able polymer-based DES result in improved arterial healing which
in turn not only minimizes the risk of stent thrombosis but also
improves the long-term durability of the antirestenotic efficacy.
The present study has several limitations. First, this is not a ran-
domized clinical trial, but a pooled analysis of individual patient
data from three different randomized clinical trials. However, the
trials primarily intended to investigate biodegradable polymer
DES vs. durable polymer DES consistent with the aim of the
present analysis. In addition, we used a statistically conservative
meta-analytical model rather than the less robust method of
simple data pooling with standard statistical testing. Moreover,
our analyses showed no evidence of heterogeneity across the
trials and pooled individual patient data revealed no significant dif-
ference between the two compared groups at baseline. Secondly,
inclusion criteria were not equivalent across the included trials.
Nevertheless, the high overall prevalence of acute myocardial in-
farction at baseline as well as the relatively complex angiographic
characteristics reflects the broadly inclusive nature of the included
patient population. Thirdly, only sirolimus-eluting durable polymer
DES were included in the present comparison, and therefore the
results cannot be extended to other available durable polymer
DES. However, durable polymer SES represents the gold standard
among early generation DES, and performance differences with
newer generation durable polymer DES—such as everolimus-
eluting and zotarolimus-eluting stents—vs. SES is still a matter of
some debate.32 Finally, two different biodegradable polymer
stents were included in the analysis, and although the coatings of
both stents contain polylactic acid monomers and limus-agent
drugs, differences in polymer degradation and drug release kinetics
between the two stents may be expected.
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Table 3 Clinical outcomes in landmark analysis (1–4 years)
Biodegradable polymer
DES (n5 2358)
Durable polymer
SES (n5 1704)
HR (95% CI) P-value
1–4 years
Death 114 (5.6) 99 (6.5) 0.85 (0.65–1.12) 0.26
Cardiac death 58 (2.9) 48 (3.2) 0.95 (0.64–1.40) 0.79
Myocardial infarction 29 (1.5) 42 (3.0) 0.59 (0.37–0.95) 0.031
Definite stent thrombosis 4 (0.2) 18 (1.3) 0.22 (0.08–0.61) 0.004
Clinically indicated TLR 102 (5.2) 86 (6.3) 0.81 (0.60–1.09) 0.16
Cardiac death or myocardial infarction 76 (3.9) 84 (5.9) 0.73 (0.53–1.00) 0.050
Cardiac death, myocardial infarction, or clinically indicated
TLR
154 (8.2) 140 (10.4) 0.79 (0.63–1.00) 0.048
Events are reported as number (percentage from Kaplan–Meier estimate); hazard ratios and P-values were calculated using random effects meta-analysis. CI, confidence interval;
DES, drug-eluting stents; SES, sirolimus-eluting stents; TLR, target lesion revascularization.
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Figure 1 Efficacy endpoint: target lesion revascularization. (A) Kaplan–Meier curves for the pooled population in each of the stent groups.
(B) Forest plot with hazard ratios with biodegradable polymer stents vs. permanent polymer stents for individual trials and the pooled popu-
lation. Hazard ratios are shown on a logarithmic scale. The size of the square is proportional to the weight of the individual studies, measured as
the inverse of the estimated variance of the log hazard ratio. BP, biodegradable polymer drug-eluting stent; DP, durable polymer
sirolimus-eluting stent. (C) Kaplan–Meier curves for the pooled population in each of the stent groups with the landmark analysis at 1 year.
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Figure 2 Safety endpoint: definite stent thrombosis. (A) Kaplan–Meier curves for the pooled population in each of the stent groups.
(B) Forest plot with hazard ratios for biodegradable polymer stents vs. permanent polymer stents for individual trials and the pooled population.
Hazard ratios are shown on a logarithmic scale. The size of the square is proportional to the weight of the individual studies, measured as the
inverse of the estimated variance of the log hazard ratio. BP, biodegradable polymer drug-eluting stent; DP, durable polymer sirolimus-eluting
stent. (C) Kaplan–Meier curves for the pooled population in each of the stent groups with the landmark analysis at 1 year.
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Conclusions
Biodegradable polymer DES improve safety and efficacy compared
with durable polymer SES during long-term follow-up to 4 years.
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A patient with angina at night: core curriculum chapters 3 (non-invasive
imaging) and 9 (chronic ischaemic heart disease)
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This diabetic 66-year-old male patient had episodes of nightly angina,
but then was symptom free and could be exercised without symptoms.
His ECG at rest (Figure) showed T-wave inversion in II, III, avF, and V5
and V6. How should this patient be worked up? Should he have non-
invasive testing, and if so, which kind? If coronary artery disease amen-
able to revascularization was found, is there an indication to perform it?
Follow us step-by-step through this typical scenario. Explore the full
case on the ESC’s case-based learning website at www.escardio.org/
education/eLearning/clinical-cases.
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